Literature DB >> 28505261

Survival and Causes of Death Among People With Clinically Diagnosed Synucleinopathies With Parkinsonism: A Population-Based Study.

Rodolfo Savica1, Brandon R Grossardt2, James H Bower3, J Eric Ahlskog3, Bradley F Boeve3, Jonathan Graff-Radford3, Walter A Rocca1, Michelle M Mielke1.   

Abstract

Importance: To our knowledge, a comprehensive study of the survival and causes of death of persons with synucleinopathies compared with the general population has not been conducted. Understanding the long-term outcomes of these conditions may inform patients and caregivers of the expected disease duration and may help with care planning. Objective: To compare survival rates and causes of death among patients with incident, clinically diagnosed synucleinopathies and age- and sex-matched referent participants. Design, Setting, and Participants: This population-based study used the Rochester Epidemiology Project medical records-linkage system to identify all residents in Olmsted County, Minnesota, who received a diagnostic code of parkinsonism from 1991 through 2010. A movement-disorders specialist reviewed the medical records of each individual to confirm the presence of parkinsonism and determine the type of synucleinopathy. For each confirmed patient, an age- and sex-matched Olmsted County resident without parkinsonism was also identified. Main Outcomes and Measures: We determined the age- and sex-adjusted risk of death for each type of synucleinopathy, the median time from diagnosis to death, and the causes of death.
Results: Of the 461 patients with synucleinopathies, 279 (60.5%) were men, and of the 452 referent participants, 272 (60.2%) were men. From 1991 through 2010, 461 individuals received a diagnosis of a synucleinopathy (309 [67%] of Parkinson disease, 81 [17.6%] of dementia with Lewy bodies, 55 [11.9%] of Parkinson disease dementia, and 16 [3.5%] of multiple system atrophy with parkinsonism). During follow-up, 68.6% (n = 316) of the patients with synucleinopathies and 48.7% (n = 220) of the referent participants died. Patients with any synucleinopathy died a median of 2 years earlier than referent participants. Patients with multiple system atrophy with parkinsonism (hazard ratio, 10.51; 95% CI, 2.92-37.82) had the highest risk of death compared with referent participants, followed by those with dementia with Lewy bodies (hazard ratio, 3.94; 95% CI, 2.61-5.94), Parkinson disease with dementia (hazard ratio, 3.86; 95% CI, 2.36-6.30), and Parkinson disease (hazard ratio, 1.75; 95% CI, 1.39-2.21). Neurodegenerative disease was the most frequent cause of death listed on the death certificate for patients, and cardiovascular disease was the most frequent cause of death among referent participants. Conclusions and Relevance: Individuals with multiple system atrophy with parkinsonism, dementia with Lewy bodies, and Parkinson disease dementia have increased mortality compared with the general population. The mortality among persons with Parkinson disease is only moderately increased compared with the general population.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28505261      PMCID: PMC5647647          DOI: 10.1001/jamaneurol.2017.0603

Source DB:  PubMed          Journal:  JAMA Neurol        ISSN: 2168-6149            Impact factor:   18.302


  42 in total

1.  Trends in causes of death among the elderly.

Authors:  N R Sahyoun; H Lentzner; D Hoyert; K N Robinson
Journal:  Aging Trends       Date:  2001-03

2.  Predictors of survival in dementia with lewy bodies and Parkinson dementia.

Authors:  Kurt A Jellinger; Gregor K Wenning; Klaus Seppi
Journal:  Neurodegener Dis       Date:  2007-10-09       Impact factor: 2.977

3.  Survival of patients with pathologically proven multiple system atrophy: a meta-analysis.

Authors:  Y Ben-Shlomo; G K Wenning; F Tison; N P Quinn
Journal:  Neurology       Date:  1997-02       Impact factor: 9.910

4.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

5.  Mortality in patients with Parkinson's disease.

Authors:  L Wermuth; E N Stenager; E Stenager; J Boldsen
Journal:  Acta Neurol Scand       Date:  1995-07       Impact factor: 3.209

6.  Evidence against the operation of selective mortality in explaining the association between cigarette smoking and reduced occurrence of idiopathic Parkinson disease.

Authors:  D M Morens; A Grandinetti; J W Davis; G W Ross; L R White; D Reed
Journal:  Am J Epidemiol       Date:  1996-08-15       Impact factor: 4.897

7.  Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Am J Epidemiol       Date:  2011-03-23       Impact factor: 4.897

8.  Rapidly progressive neurodegenerative dementias.

Authors:  Keith A Josephs; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Brian A Crum; Caterina Giannini; Ronald C Petersen
Journal:  Arch Neurol       Date:  2009-02

9.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

10.  The association between Parkinson's disease and melanoma: a systematic review and meta-analysis.

Authors:  Pei Huang; Xiao-Dong Yang; Sheng-Di Chen; Qin Xiao
Journal:  Transl Neurodegener       Date:  2015-11-03       Impact factor: 8.014

View more
  23 in total

1.  Survival and Progression in Synucleinopathy Phenotypes With Parkinsonism: A Population-Based Study.

Authors:  Rodolfo Savica; Pierpaolo Turcano; James H Bower; J Eric Ahlskog; Michelle M Mielke
Journal:  Mayo Clin Proc       Date:  2019-08-09       Impact factor: 7.616

Review 2.  Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2017-12-08       Impact factor: 3.575

3.  Infections or Sepsis Preceding Clinically Diagnosed α-Synucleinopathies: A Case-Control Study.

Authors:  Shemonti Hasan; Michelle M Mielke; J Eric Ahlskog; James Bower; Pierpaolo Turcano; Rodolfo Savica
Journal:  Mov Disord       Date:  2020-06-01       Impact factor: 10.338

4.  Parkinson disease with and without Dementia: A prevalence study and future projections.

Authors:  Rodolfo Savica; Brandon R Grossardt; Walter A Rocca; James H Bower
Journal:  Mov Disord       Date:  2018-01-22       Impact factor: 10.338

5.  The impact of supine hypertension on target organ damage and survival in patients with synucleinopathies and neurogenic orthostatic hypotension.

Authors:  Jose-Alberto Palma; Gabriel Redel-Traub; Angelo Porciuncula; Daniela Samaniego-Toro; Patricio Millar Vernetti; Yvonne W Lui; Lucy Norcliffe-Kaufmann; Horacio Kaufmann
Journal:  Parkinsonism Relat Disord       Date:  2020-05-18       Impact factor: 4.891

6.  The Pentagon Copying Test and the Clock Drawing Test as Prognostic Markers in Dementia with Lewy Bodies.

Authors:  Leonie J M Vergouw; Mariet Salomé; Anke G Kerklaan; Christiaan Kies; Gerwin Roks; Esther van den Berg; Frank Jan de Jong
Journal:  Dement Geriatr Cogn Disord       Date:  2018-07-11       Impact factor: 2.959

7.  Traumatic brain injury preceding clinically diagnosed α-synucleinopathies: A case-control study.

Authors:  Shemonti Hasan; Michelle M Mielke; Pierpaolo Turcano; J Eric Ahlskog; James H Bower; Rodolfo Savica
Journal:  Neurology       Date:  2020-01-28       Impact factor: 11.800

8.  Are dementia with Lewy bodies and Parkinson's disease dementia the same disease?

Authors:  Kurt A Jellinger; Amos D Korczyn
Journal:  BMC Med       Date:  2018-03-06       Impact factor: 8.775

Review 9.  MPTP-induced mouse model of Parkinson's disease: A promising direction of therapeutic strategies.

Authors:  Musa Mustapha; Che Norma Mat Taib
Journal:  Bosn J Basic Med Sci       Date:  2021-08-01       Impact factor: 3.363

10.  Early-Onset Parkinsonism and Early-Onset Parkinson's Disease: A Population-Based Study (2010-2015).

Authors:  Emanuele Camerucci; Cole D Stang; Mania Hajeb; Pierpaolo Turcano; Aidan F Mullan; Peter Martin; Owen A Ross; James H Bower; Michelle M Mielke; Rodolfo Savica
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.